XYLO Stock Overview
A technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Xylo Technologies Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.23 |
| 52 Week High | US$10.43 |
| 52 Week Low | US$2.70 |
| Beta | 1.49 |
| 1 Month Change | 2.70% |
| 3 Month Change | -11.51% |
| 1 Year Change | -68.33% |
| 3 Year Change | -92.24% |
| 5 Year Change | -95.59% |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Medigus says ScoutCam appoints Yehu Ofer as CEO
Oct 19Medigus reports 1H results
Sep 23What Does Medigus Ltd.'s (NASDAQ:MDGS) Share Price Indicate?
Sep 22
Medigus board files a motion to approve an up to $1.6M dividend distribution
Sep 08Is Now An Opportune Moment To Examine Medigus Ltd. (NASDAQ:MDGS)?
May 10We Believe Medigus' (NASDAQ:MDGS) Earnings Are A Poor Guide For Its Profitability
Sep 28Medigus jumps 4% as subsidiary Charging Robotics assigns first distributor for its wireless EV robotic charging pad
Jun 17Medigus launches ADS offering
Jan 11Medigus expands EV operations with acquisition of autonomous technology, shares up 31%
Jan 08New finance cheif at Medigus
Dec 01Medigus shares +42% on plans to enter micro-mobility EV market
Nov 19Medigus under pressure after increasing stake to ~33% in Polyrizon
Nov 09Shareholder Returns
| XYLO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -10.3% | -1.5% | -2.4% |
| 1Y | -68.3% | 10.1% | 23.3% |
Return vs Industry: XYLO underperformed the US Medical Equipment industry which returned 9% over the past year.
Return vs Market: XYLO underperformed the US Market which returned 22.1% over the past year.
Price Volatility
| XYLO volatility | |
|---|---|
| XYLO Average Weekly Movement | 10.8% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XYLO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XYLO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 84 | Liron Carmel | www.medigus.com |
Xylo Technologies Ltd, a technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally. The company operates through Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Others segments. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease.
Xylo Technologies Ltd Fundamentals Summary
| XYLO fundamental statistics | |
|---|---|
| Market cap | US$2.27m |
| Earnings (TTM) | -US$15.99m |
| Revenue (TTM) | US$57.64m |
0.0x
P/S Ratio-0.1x
P/E RatioIs XYLO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XYLO income statement (TTM) | |
|---|---|
| Revenue | US$57.64m |
| Cost of Revenue | US$49.84m |
| Gross Profit | US$7.80m |
| Other Expenses | US$23.79m |
| Earnings | -US$15.99m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -21.84 |
| Gross Margin | 13.53% |
| Net Profit Margin | -27.74% |
| Debt/Equity Ratio | 40.7% |
How did XYLO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 02:59 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xylo Technologies Ltd is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rommel Dionisio | Aegis Capital Corporation |
| Jeffrey Cohen | Ladenburg Thalmann & Company |
| Christopher Lewis | Roth MKM |